Ani Pharmaceuticals Inc (ANIP) Profitability Comparisons, Net Margin, Gross Margin, Tax rate, Cash Flow Margin Comparisons - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Ani Pharmaceuticals Inc  (NASDAQ: ANIP)

Ani Pharmaceuticals Inc Profitability Comparisons

Select each Category to receive further Information



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ANIP Profitability Ratio

 Company Industry Sector S&P 500
Gross Profit Margin (Q2 MRQ) 62.35 % 70.91 % 65.43 % 46.08 %
Gross Margin (Q2 TTM) 60.4 % 71.7 % 65.99 % 46.3 %
Gross Profit Margin 5 Yr. Avg. 58.59 % 67.81 % 65.55 % 48.95 %
EBITDA Margin (Q2 MRQ) 33.75 % 21.45 % 18.99 % 20.49 %
EBITDA Margin (Q2 TTM) 28.49 % 25.15 % 21.01 % 20.13 %
EBITDA Margin 5 Yr. Avg. 17.92 % 47.09 % 31.38 % 23.41 %
Operating Margin (Q2 MRQ) 15.21 % 17.27 % 16.58 % 16.05 %
Operating Margin (Q2 TTM) 15.37 % 20.33 % 17.81 % 16.34 %
Operating Margin 5 Yr. Avg. --1.45 % 15.37 % 14.33 % 19.26 %
Pre-Tax Profit Margin (Q2 MRQ) 13.94 % 13.66 % 10.94 % 13.96 %
Pre-Tax Profit Margin (Q2 TTM) 14.57 % 16.7 % 12.79 % 13.09 %
Pre-Tax Profit Margin 5 Yr. Avg. - 12.98 % 10.37 % 13.52 %
Net Margin (Q2 MRQ) 8.65 % 10.09 % 8.15 % 11.42 %
Net Margin (Q2 TTM) 10.9 % 13.13 % 9.94 % 10.76 %
Net Margin 5 Yr. Avg. - 5.79 % 6.08 % 10.8 %



Business Segment Profit Margin
 
Brands
  Explore Brands Segment  -
Generics and Other
  Explore Generics and Other Segment  36.6 %
Rare Disease and Brands
  Explore Rare Disease and Brands Segment  30.17 %
Sales of Cortrophin Gel
  Explore Sales of Cortrophin Gel Segment  -
Sales of ILUVIEN and YUTIQ
  Explore Sales of ILUVIEN and YUTIQ Segment  -
Total sales of rare disease pharmaceutical products
  Explore Total sales of rare disease pharmaceutical products Segment  -
Sales of Established Brands
  Explore Sales of Established Brands Segment  -
Sales of Established Brand Royalties and Other Revenues
  Explore Sales of Established Brand Royalties and Other Revenues Segment  -
Total Sales of Rare Disease and Brands
  Explore Total Sales of Rare Disease and Brands Segment  -
Sales of generic pharmaceutical products
  Explore Sales of generic pharmaceutical products Segment  -
Sales of Generic Other Revenues
  Explore Sales of Generic Other Revenues Segment  -
Total Sales of Generics and Other
  Explore Total Sales of Generics and Other Segment  -
 

Company's Cashflow Profitability & Other



Profitability Ratios Company Industry Sector S&P 500
Free Cash Flow Margin (Q2 MRQ) 20.15 % -0.01 % 0.21 % 1.39 %
Free Cash Flow Margin (Q2 TTM) 17.12 % 17.24 % 13.85 % 9.11 %
Free Cash Flow Margin 5 Yr. Avg. - 19.28 % 14.86 % 15.58 %
Net Cash Flow Margin (Q2 MRQ) 0 % 0.02 % -0.02 % 0.13 %
Net Cash Flow Margin (Q2 TTM) 9.54 % -0.66 % 0.13 % 1.85 %
Net Cash Flow Margin 5 Yr. Avg. - 4.38 % 3.16 % 6.44 %
Effective Tax Rate (Q2 MRQ) 33.39 % 25.98 % 25.39 % 18.83 %
Effective Tax Rate (Q2 TTM) 24.04 % 21.21 % 22.93 % 19.44 %
Effective Tax Rate 5 Yr. Avg. - 15.08 % 20.51 % 19.76 %
Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.